RxDoctor Payments Data

Arthur Ayvazian, MD

Family Medicine · Pasadena, CANPI 1023500527

Payments from drug & device makers

$771in general payments, 2019–2025

Across 15 payments — averaging $51.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$200
  • Inspire Medical Systems, Inc.$141
  • Edwards Lifesciences$139
  • Organogenesis Inc.$125
  • Dexcom, Inc.$72
  • Novo Nordisk$32
  • plus $61 from 3 others

What the payments were for

  • Food & beverage$73996%
  • Education$324%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$771 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$102,341
Medicare patients
246
Services billed
1,026

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin59$56,519
MounjaroTirzepatide45$46,773
EliquisApixaban44$38,747
OzempicSemaglutide42$38,308
RybelsusSemaglutide22$29,469
LinzessLinaclotide15$7,964
Synjardy XrEmpagliflozin/Metformin Hcl12$6,313
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$3,533
Atorvastatin Calcium272$2,284
Duloxetine Hcl94$2,123
Rosuvastatin Calcium163$1,949
SynthroidLevothyroxine Sodium18$1,626
Valsartan58$1,485
Metoprolol Succinate76$1,297
Amlodipine Besylate216$963

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$32$67,77664 claims
Lilly USA, LLCMounjaro$30$46,77345 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,533 family medicine providers in California.

Other family medicine in Pasadena

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →